Sarepta Therapeutics
SRPT
Performance
About Sarepta Therapeutics
Sarepta Therapeutics is a global biotechnology company focused on precision genetic medicines to treat rare neuromuscular and central nervous system diseases. The company is advancing gene therapy and RNA-based approaches with an emphasis on Duchenne muscular dystrophy and related rare disorders, and is building manufacturing capacity to speed patient access. Headquartered with global operations, Sarepta collaborates across scientists, patients, and partners to bring transformative therapies to underserved populations.
Recent News
Marty Makary Steps Down as FDA Commissioner After Complaints, Adding to Regulatory Uncertainties
4 Spaces Primed for the Next Wave of Gene Therapies
Federal Circuit’s Holding on Patent Eligibility for Engineered Host Cells Dovetails With PERA
Sarepta, Amylyx and Neumora Look Ahead to Key Catalysts as Q1 Earnings Roll In
Biotech Insights - Spring 2026
PTAB Denies Institution of One Elevidys® IPR and Institutes Another
Aurora Sets Out to Capitalize on FDA’s New Framework for Bespoke Drug Therapies
REGENXBIO's RGX-202 Gene Therapy Hits Pivotal Efficacy Endpoint in Duchenne Trial
Dyne Therapeutics Files BLA for Z‑Rostudirsen, Seeks Priority Review for DMD Treatment
The Most Expensive Drugs on the Market in 2026 — and Why They Cost So Much
Rampart Closes Down Less Than 2 Years After Launch
Regenxbio’s RGX-202 Gene Therapy Hits Primary Endpoint in Phase 3 Duchenne Trial
BIO on the American Road Tours Gene Therapy Hub in Ohio
Atrium Therapeutics Inc (RNA) Q1 2026 Earnings Call Transcript
Sarepta Saga Has 'Gone on Too Long' As Competitors Catch Up
STAT+: Roche to Launch Another Elevidys Trial, with Eyes on European Approval
FDA Reverses Course on Atara, Pierre Fabre’s Twice-Rejected Cell Therapy After Prasad’s Exit
Roche to Start Phase III Trial to Broaden Access to Elevidys in Duchenne Muscular Dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
FDA Taps Szarama as Acting CBER Director as Prasad’s Tumultuous Tenure Ends
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
Roche Launches New Elevidys Trial to Address EU Rejection in Duchenne Therapy Bid
Entrada Crashes as Duchenne Therapy Comes in ‘Below Expectations’ in Early Study
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026
FDA Accepts BridgeBio’s Application for Potential First Limb-Girdle Muscular Dystrophy Drug
Sarepta Touts Three-Year Duchenne Gene Therapy Data After Patient Deaths
STAT+: Cochrane Review Reignites Alzheimer’s Amyloid Wars
Gene Therapy’s Evidence Problem—Lessons From Recent FDA Decisions
Approaches to Reducing Toxicity and Side Effects in Cell and Gene Therapy
Recent Deals
No recent deals for this company.